Similarly, several evidence suggest that molecular therapies targeting metabolic vulnerabilities in IDH-mutated gliomas and acute myeloid leukemia have proven beneficial and emerged as promising therapeutic strategies for improving patient prognosis. This evidence concerns the gene IDH2 and glioma.